A detailed history of Mount Vernon Associates Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mount Vernon Associates Inc holds 29,779 shares of BMY stock, worth $1.61 Million. This represents 1.1% of its overall portfolio holdings.

Number of Shares
29,779
Previous 29,619 0.54%
Holding current value
$1.61 Million
Previous $1.61 Million 22.98%
% of portfolio
1.1%
Previous 1.42%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$40.25 - $52.99 $6,440 - $8,478
160 Added 0.54%
29,779 $1.24 Million
Q1 2024

Apr 22, 2024

BUY
$47.98 - $54.4 $6,669 - $7,561
139 Added 0.47%
29,619 $1.61 Million
Q4 2023

Jan 26, 2024

BUY
$48.48 - $57.85 $96,960 - $115,700
2,000 Added 7.28%
29,480 $1.51 Million
Q3 2023

Oct 24, 2023

BUY
$57.89 - $64.73 $23,792 - $26,604
411 Added 1.52%
27,480 $1.6 Million
Q2 2023

Jul 24, 2023

BUY
$63.71 - $70.74 $17,520 - $19,453
275 Added 1.03%
27,069 $1.73 Million
Q1 2023

Apr 20, 2023

SELL
$65.71 - $74.53 $36,140 - $40,991
-550 Reduced 2.01%
26,794 $1.86 Million
Q3 2022

Oct 21, 2022

BUY
$0.13 - $76.84 $24 - $14,599
190 Added 0.7%
27,344 $1.94 Million
Q1 2022

Apr 25, 2022

BUY
$61.48 - $73.72 $23,055 - $27,645
375 Added 1.4%
27,154 $1.98 Million
Q4 2021

Jan 25, 2022

BUY
$53.63 - $62.52 $8,044 - $9,378
150 Added 0.56%
26,779 $1.67 Million
Q3 2021

Oct 20, 2021

BUY
$59.17 - $69.31 $11,834 - $13,862
200 Added 0.76%
26,629 $1.58 Million
Q4 2020

Jan 25, 2021

BUY
$57.74 - $65.43 $5,774 - $6,543
100 Added 0.38%
26,429 $1.64 Million
Q3 2020

Oct 23, 2020

SELL
$57.43 - $63.64 $14,357 - $15,910
-250 Reduced 0.94%
26,329 $1.59 Million
Q2 2020

Jul 27, 2020

SELL
$54.82 - $64.09 $7,236 - $8,459
-132 Reduced 0.49%
26,579 $1.56 Million
Q1 2020

Apr 23, 2020

BUY
$46.4 - $67.43 $38,651 - $56,169
833 Added 3.22%
26,711 $1.49 Million
Q4 2019

Jan 24, 2020

SELL
$49.21 - $64.19 $7,381 - $9,628
-150 Reduced 0.58%
25,878 $1.66 Million
Q3 2019

Oct 16, 2019

SELL
$42.77 - $50.71 $17,108 - $20,284
-400 Reduced 1.51%
26,028 $1.32 Million
Q2 2019

Jul 30, 2019

SELL
$44.62 - $49.34 $955,314 - $1.06 Million
-21,410 Reduced 44.76%
26,428 $1.2 Million
Q2 2019

Jul 25, 2019

BUY
$44.62 - $49.34 $955,314 - $1.06 Million
21,410 Added 81.01%
47,838 $2.17 Million
Q1 2019

Apr 25, 2019

SELL
$45.12 - $53.8 $7,128 - $8,500
-158 Reduced 0.59%
26,428 $1.26 Million
Q4 2018

Jan 24, 2019

SELL
$48.76 - $63.23 $39,008 - $50,584
-800 Reduced 2.92%
26,586 $1.38 Million
Q3 2018

Oct 22, 2018

BUY
$55.19 - $62.25 $2,373 - $2,676
43 Added 0.16%
27,386 $1.7 Million
Q2 2018

Jul 27, 2018

SELL
$50.53 - $62.98 $80,848 - $100,768
-1,600 Reduced 5.53%
27,343 $1.51 Million
Q1 2018

Apr 19, 2018

SELL
$59.92 - $68.98 $23,968 - $27,592
-400 Reduced 1.36%
28,943 $1.83 Million
Q3 2017

Oct 24, 2017

BUY
$55.23 - $63.74 $1.62 Million - $1.87 Million
29,343
29,343 $1.87 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Mount Vernon Associates Inc Portfolio

Follow Mount Vernon Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mount Vernon Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mount Vernon Associates Inc with notifications on news.